iShares US Pharmaceuticals ETF
87 hedge funds and large institutions have $197M invested in iShares US Pharmaceuticals ETF in 2016 Q2 according to their latest regulatory filings, with 7 funds opening new positions, 20 increasing their positions, 39 reducing their positions, and 11 closing their positions.
0% more funds holding in top 10
Funds holding in top 10: 3 → 3 (0)
4% less capital invested
Capital invested by funds: $205M → $197M (-$8.14M)
2.46% less ownership
Funds ownership: 97.38% → 94.92% (-2.5%)
4% less funds holding
Funds holding: 91 → 87 (-4)
36% less first-time investments, than exits
New positions opened: 7 | Existing positions closed: 11
49% less repeat investments, than reductions
Existing positions increased: 20 | Existing positions reduced: 39
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
+$10.3M |
| 2 |
VF
Virtu Financial
New York
|
+$2.76M |
| 3 |
Citadel Advisors
Miami,
Florida
|
+$1.98M |
| 4 |
MFS
MSI Financial Services
Springfield,
Massachusetts
|
+$729K |
| 5 |
Envestnet Asset Management
Chicago,
Illinois
|
+$599K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
LPL Financial
San Diego,
California
|
-$6.76M |
| 2 |
Bank of America
Charlotte,
North Carolina
|
-$4.91M |
| 3 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$4.02M |
| 4 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
-$2.52M |
| 5 |
SFI
SPC Financial Inc
Rockville,
Maryland
|
-$2.34M |
IHE Hedge Fund Activity: Q2 2016 in Review
87 of the 3,748 institutional investors tracked by Wall St. Rank reported a position in iShares US Pharmaceuticals ETF (IHE) for Q2 2016, worth a combined $197M — down 4% from $205M a quarter earlier.
Sellers outnumbered buyers: 11 funds closed out of IHE and 7 opened new positions — a net loss of 4 holders — while 39 trimmed existing stakes and 20 added.
The largest buyer was Morgan Stanley, adding an estimated $10.3M. The largest seller was LPL Financial, cutting an estimated $6.76M.
- 87 institutional investors held iShares US Pharmaceuticals ETF (IHE) as of Q2 2016, down from 91 in Q1 2016.
- Funds reported $197M of iShares US Pharmaceuticals ETF stock for Q2 2016, down 4% quarter-over-quarter.
- 7 funds opened new iShares US Pharmaceuticals ETF positions in Q2 2016 and 11 closed out, a net change of -4 holders.
- The largest iShares US Pharmaceuticals ETF buyer in Q2 2016 was Morgan Stanley, an estimated $10.3M added.
- The largest iShares US Pharmaceuticals ETF seller in Q2 2016 was LPL Financial, an estimated $6.76M sold.
Based on aggregated 13F filings for Q2 2016.